Tear cytokine levels are reduced in patients treated with intravitreal injections

Ocul Surf. 2024 Apr:32:222-226. doi: 10.1016/j.jtos.2024.03.004. Epub 2024 Mar 13.

Abstract

Purpose: To investigate cytokine levels in the tear fluid of patients receiving serial intravitreal injections (IVI) with anti-vascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (nAMD).

Methods: Concentrations of six cytokines (IFN-γ, IL-1β, IL-6, IL-8, TNF and VEGF) in tears of patients receiving anti-VEGF in one eye were assayed using multiplex cytometric bead array. The fellow untreated eye served as control. Tear sampling was performed on a single occasion at a minimum of four weeks after IVI. Patients underwent a pre-IVI antisepsis protocol with povidone-iodine.

Results: Tear fluid from thirty patients with a mean age of 78.8 years (range 58-90) was assayed. Subjects received a median of 43.5 (range 22-106) IVI in one eye. The median level of IFN-γ was 0.33 (interquartile range (IQR) 0.22-0.52) pg/mg of total protein in injected eyes versus 0.41 (IQR 0.21-1.05) pg/mg in fellow eyes (p = 0.017). For TNF, a median level of 0.12 (IQR 0.08-0.18) pg/mg of total protein was found in injected eyes versus 0.14 (IQR 0.07-0.33) pg/mg of total protein in fellow eyes (p = 0.019). There were no differences between injected and fellow eyes regarding the levels of IL-1β, IL-6, IL-8 and VEGF.

Conclusion: Tear fluid in eyes receiving serial IVI with anti-VEGF and preoperative povidone-iodine antisepsis constitutes lower levels of the pro-inflammatory cytokines IFN-γ and TNF compared to fellow eyes. This provides biochemical support of previous findings of reduced signs of inflammation and healthier tear film parameters in patients treated with serial IVI.

Keywords: Anti-VEGF; Cytokines; Dry eye disease; Intravitreal injections; Povidone iodine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors* / administration & dosage
  • Angiogenesis Inhibitors* / therapeutic use
  • Cytokines* / metabolism
  • Female
  • Humans
  • Intravitreal Injections*
  • Male
  • Middle Aged
  • Prospective Studies
  • Ranibizumab / administration & dosage
  • Ranibizumab / therapeutic use
  • Tears* / metabolism
  • Vascular Endothelial Growth Factor A / metabolism
  • Wet Macular Degeneration / drug therapy
  • Wet Macular Degeneration / metabolism

Substances

  • Cytokines
  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Ranibizumab